The attitudes, knowledge and confidence of healthcare professionals about cannabis-based products

被引:0
作者
Russo, Emilio [1 ]
Agredano, Paula Martinez [2 ]
Flachenecker, Peter [3 ]
Lawthom, Charlotte [4 ]
Munro, Duncan [5 ]
Hindocha, Chandni [6 ]
Bagul, Makarand [6 ]
Trinka, Eugen [7 ,8 ,9 ]
机构
[1] Magna Grecia Univ, Sci Hlth Dept, Catanzaro, Italy
[2] Univ Hosp Reina Sofia, Cordoba, Spain
[3] Neurol Rehabil Ctr Quellenhof, Bad Wildbad, Germany
[4] Univ Swansea, Swansea, Wales
[5] Lumanity, London, England
[6] GW Pharmaceut, Cambridge, England
[7] Paracelsus Med Univ, Christian Doppler Univ Hosp, Ctr Cognit Neurosci Salzburg, EpiCARE,Dept Neurol,European Reference Network, Salzburg, Austria
[8] Paracelsus Med Univ, Neurosci Inst, Christian Doppler Med Ctr, Ctr Cognit Neurosci Salzburg, Salzburg, Austria
[9] Karl Landsteiner Inst Neurorehabil & Space Neurol, Salzburg, Austria
关键词
Healthcare professional education; Survey; Cannabis; Cannabinoids; Cannabis-based product; Cannabis-based medicine; ENDOCANNABINOIDS; PHYTOCANNABINOIDS; EPILEPSY;
D O I
10.1186/s42238-024-00242-y
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
BackgroundUse of cannabis-based products is becoming more frequent, and it is important that healthcare professionals are informed and confident about them when making evidence-based decisions about their use. This study aimed to gain an international perspective on the attitudes, knowledge, and confidence of healthcare professionals about cannabis-based products.MethodsAn online questionnaire regarding these products was completed by 1580 healthcare professionals (neurologists, psychiatrists, general practitioners, pharmacists and nurses) from 16 countries across Asia, Europe, Oceania, South America, and the Middle East.ResultsRespondents expressed a high level of interest in cannabis-based products (median score 9 out of 10) and reported that they felt knowledgeable about them (median score 6 out of 7). They reported a high level of confidence when providing patients with information on cannabis-based products, returning median scores of 6 and 5 out of 7 for their legality and regulations, and their benefits and risks, respectively. Despite this, healthcare professionals sought further information on cannabis-based products across areas including legality, neurobiology, and scientific evidence. Finally, 59% (n = 930) of respondents considered robust clinical trial evidence as the most important factor to ensure patient safety in the context of these products. Few nominally significant differences emerged between healthcare professionals from different specialities or regions.ConclusionIn conclusion, this large survey of attitudes held by healthcare professionals towards cannabis-based products revealed a high level of interest and a demand for more information. Limitations of this study include potential sample bias and limited external validity.
引用
收藏
页数:13
相关论文
共 40 条
[11]   Colorado Medical Students' Attitudes and Beliefs About Marijuana [J].
Chan, Michael H. ;
Knoepke, Christopher E. ;
Cole, Madeline L. ;
McKinnon, James ;
Matlock, Daniel D. .
JOURNAL OF GENERAL INTERNAL MEDICINE, 2017, 32 (04) :458-463
[12]   Lack of evidence for the effectiveness or safety of over-the-counter cannabidiol products [J].
Chesney, Edward ;
McGuire, Philip ;
Freeman, Tom P. ;
Strang, John ;
Englund, Amir .
THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY, 2020, 10
[13]   Cannabinoids and the expanded endocannabinoid system in neurological disorders [J].
Cristino, Luigia ;
Bisogno, Tiziana ;
Di Marzo, Vincenzo .
NATURE REVIEWS NEUROLOGY, 2020, 16 (01) :9-29
[14]   ISOLATION AND STRUCTURE OF A BRAIN CONSTITUENT THAT BINDS TO THE CANNABINOID RECEPTOR [J].
DEVANE, WA ;
HANUS, L ;
BREUER, A ;
PERTWEE, RG ;
STEVENSON, LA ;
GRIFFIN, G ;
GIBSON, D ;
MANDELBAUM, A ;
ETINGER, A ;
MECHOULAM, R .
SCIENCE, 1992, 258 (5090) :1946-1949
[15]   Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action [J].
Di Marzo, V ;
Melck, D ;
Bisogno, T ;
De Petrocellis, L .
TRENDS IN NEUROSCIENCES, 1998, 21 (12) :521-528
[16]   Neurologists' perspectives on medical cannabis for pediatric drug-resistant epilepsy in Canada: A qualitative interview study [J].
Elliott, Jesse ;
DeJean, Deirdre ;
Potter, Beth K. ;
Coyle, Doug ;
Clifford, Tammy ;
McCoy, Blathnaid ;
Wells, George A. .
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2020, 78 :118-126
[17]  
European Medicines Agency, 2021, Epidyolex: EPAR-Product information: European Medicines Agency
[18]  
European Medicines Agency, 2016, The European regulatory system for medicines: a consistent approach to medicines regulation across the European Union
[19]  
European Monitoring Centre for Drugs and Drug Addiction, Medical use of cannabis and cannabinoids 2018
[20]  
European Pharmaceutical Market Research Association (EPhMRA), 2022, COD COND